



Mark Pegram

Susy Yuan-Huey Hung Professor
Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Womens Cancer Center**

900 Blake Wilbur
MC 5348
Palo Alto, CA 94304
Tel (650) 498-6004

Fax (650) 498-7237

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Connie Osborne - Administrative Assistant

Email connieo@stanford.edu

Tel 650-723-5801

Bio

BIO

Mark Pegram, MD, is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford University School of Medicine. He currently serves as the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). He also serves as the Associate Dean for Clinical Research Quality at the Stanford University School of Medicine, and is the Medical Director of the Stanford Clinical Translational Research Unit – a unit specializing in first-in-human phase I clinical trials

Dr Pegram received his medical degree from the University of North Carolina at Chapel Hill. He went on to complete an internship and residency at the University of Texas Southwestern Medical Center in Dallas. He concluded his training with a fellowship at the UCLA David Geffen School of Medicine in Los Angeles, CA.

Dr Pegram's breast cancer research is focused on the study of the cancer-associated gene that encodes HER2 and on the development of novel agents in the treatment of patients with HER2-positive metastatic breast cancer. Dr Pegram has been educating other healthcare professionals about the future impact of biosimilars in oncology practice, especially in the breast cancer treatment landscape. He has authored more than 110 publications in medical oncology, hematology, and biosimilars across different cancer types.

CLINICAL FOCUS

- Cancer > Breast Cancer
- molecular therapeutics
- Medical Oncology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Oncology
- Member, Bio-X
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Medical Director of the Stanford Clinical Translational Research Unit, Stanford School of Medicine, (2020- present)
- Associate Dean for Clinical Research Quality, Stanford School of Medicine, (2018- present)
- Associate Director for Clinical Research, Stanford Cancer Institute, (2013- present)
- Director, Stanford Breast Oncology Program, Stanford Cancer Institute, (2012-2019)
- Co-Director, Translational Oncology Research Program @ Stanford (TOP@S), Stanford Cancer Institute, (2013-2018)

HONORS AND AWARDS

- Sylvester Outstanding Cancer Research Award, University of Miami Sylvester Comprehensive Cancer Center (13 May 2011)
- 6th Annual Connie Moskow Memorial Lectureship, Robert H. Lurie Comprehensive Cancer Center of Northwestern University (11 May 2012)
- John G. Kuhn Lecture, Hematology/Oncology Pharmacy Association (21 March 2013)
- Chair, Department of Defense Breast Cancer Research Program Integration Panel, Congressionally Directed Medical Research Programs, U.S. Army Research and Materiel Command (2012)
- 2012 Keynote Lecture, American Radium Society 94th Annual Meeting, American Radium Society (29 April 2012)
- The Celebrity Cruises Award, The Breast Cancer Research Foundation (2013-2014)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2024)
- Fellowship: UCLA Division of Hematology and Oncology (1993) CA
- Residency: University of Texas Southwestern Internal Medicine Residency (1990) TX
- Medical Education: University of North Carolina School of Medicine (1986) NC
- Board Certification: Internal Medicine, American Board of Internal Medicine (1989)

COMMUNITY AND INTERNATIONAL WORK

- The 7th Princess Chulabhorn International Science Congress, Bangkok, Thailand

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Molecular mechanisms of targeted therapy resistance in breast and other cancers

CLINICAL TRIALS

- Open Label: Extension Trastuzumab Emtansine +/- Other Tx in Previous Trastuzumab Emtansine Tx, Not Recruiting
- Phase 1b Docetaxel +PF-03084014 in Metastatic/Locally Recurrent/Advanced Triple-Neg Breast Cancer, Not Recruiting
- Phase 1B PF-05082566 in Combo w/ Adotrastuzumab-Emtansine or Trastuzumab in HER2+ Breast Cancer, Not Recruiting
- Phase I AZD5363 in Advanced Solid Malignancies, Not Recruiting
- Phase I CAMELLIA: Anti-CD47 Antibody Therapy in Relapsed/Refractory Acute Myeloid Leukaemia, Not Recruiting
- Phase I G1T48 +/- Palbociclib in Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer, Not Recruiting
- Phase I SZW49 in Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers, Not Recruiting
- Phase I VX-970/M6620 in Combo w/ Cytotoxic Chemotherapy in Advanced Solid Tumors, Not Recruiting
- Phase I/II BDC-1001 Single Agent & in Combo w/ Nivolumab in Advanced HER2-Expressing Solid Tumors, Not Recruiting

- Phase I/II MEDI4276 in Select HER2-Expressing Advanced Solid Tumors, Not Recruiting
- Phase I/II Neoadjuvant Anastrozole plus AZD0530 in Postmenopausal Patients with HR+ Breast Cancer, Not Recruiting
- Phase I/II Niraparib in Combo w/Pembrolizumab in Advanced /Metastatic Triple(-) Breast/Ovarian Cancr, Not Recruiting
- Phase I/II Recombinant Hyaluronidase (rHUPH20) in Secondary Lymphedema from Local Tx of Malignancy, Not Recruiting
- Phase Ib-IIa Trastuzumab Emtansine/ Paclitaxel/ Pertuzumab in HER2-Positive Locally Advanced or MBC, Not Recruiting
- Phase II Lapatinib+XRT in Locally Advanced/Recurrent Breast Cancer & Impact on Breast CA Stem Cells, Not Recruiting
- Phase II MGAH22 in Relapsed or Refractory Advanced HER2 2+ Level Breast Cancer, Not Recruiting
- Phase II Neoadjuvant Paclitaxel +/- LCL161 in Triple Negative Breast Cancer, Not Recruiting
- Phase II Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer, Not Recruiting
- Phase II PF-03084014 in Advanced Triple-Negative Breast Ca +/- Genomic Alterations in Notch Receptor, Not Recruiting
- Phase II PM01183 in BRCA1/2-Associated or Unselected Metastatic Breast Cancer, Not Recruiting
- Phase III Capecitabine +/- Tese-taxel vs in HER2- /Hormone Receptor+ /Local Advd /Metastatic Brst Can, Not Recruiting
- Phase III Eribulin +/- Balixafortide in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer, Not Recruiting
- Phase III Margetuximab + Chemo vs Trastuzumab Plus Chemo in HER2+ Metastatic Breast Cancer, Not Recruiting
- Phase III NKTR-102 vs MD's Choice in Previously Treated Locally Recurrent/Metastatic Breast CA, Not Recruiting
- Phase III Palbociclib + Letrozole vs Letrozole 1st Line Tx in ER+/HER2- Adv Breast CA (PALOMA-2), Not Recruiting
- Phase III TrastuzumabDeruxtecan vs Physician'sChoice in HER2LOW Unresectable/Metastatic BreastCancer, Not Recruiting
- Trastuzumab Emtansine vs Trastuzumab as Adjuvant Tx in HER2-Positive Breast CA w/ Residual Tumor, Not Recruiting
- Phase IB HGS1036 in Combination With Chemotherapy in Advanced Solid Malignancies, Not Specified
- Prospective Registry of MammaPrint in Breast Cancer Patients with an intermediate Recurrence Score, Not Specified

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.** *Proceedings of the National Academy of Sciences of the United States of America*
Upton, R., Banuelos, A., Feng, D., Biswas, T., Kao, K., McKenna, K., Willingham, S., Ho, P. Y., Rosental, B., Tal, M. C., Raveh, T., Volkmer, J., Pegram, et al
2021; 118 (29)
- **A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER.**
Ma, C. X., Luo, J., Freedman, R. A., Pluard, T., Nangia, J., Lu, J., Valdez-Albini, F., Cobleigh, M., Jones, J., Lin, N. U., Winer, E., Marcom, P., Thomas, et al
AMER ASSOC CANCER RESEARCH.2021
- **Biosimilars in an era of rising oncology treatment options.** *Future oncology (London, England)*
Peeters, M., Planchard, D., Pegram, M., Goncalves, J., Bocquet, F., Jang, H., Kim, D.
2021
- **First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2+ Advanced Breast or Gastric Cancer.** *Molecular cancer therapeutics*

Pegram, M. D., Hamilton, E. P., Tan, A. R., Storniolo, A. M., Balic, K., Rosenbaum, A. I., Liang, M., He, P., Marshall, S., Scheuber, A., Das, M., Patel, M. R.
2021

- **Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Lin, N. U., Pegram, M., Sahebjam, S., Ibrahim, N., Fung, A., Cheng, A., Nicholas, A., Kirschbrown, W., Kumthekar, P.
2021: JCO2002822
- **Humanized anti-CD47 monoclonal antibody magrolimab (Hu5F9-G4) plus trastuzumab potentiates antibody-dependent cellular phagocytosis (ADCP), and cooperate to inhibit human HER2+breast cancer (BC) xenografts growth in vivo**
Upton, R., Feng, D., Banuelos, A. M., Biswas, T., Willingham, S., Kao, K. S., McKenna, K., Rosenthal, B., Tal, M. C., Volkmer, J., Pegram, M. D., Weissman, I. L.
AMER ASSOC CANCER RESEARCH.2021
- **Results From CONTESSA: A Phase 3 Study of TeseTaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2-, Hormone Receptor+ Metastatic Breast Cancer Who Have Previously Received a Taxane** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
O'Shaughnessy, J., Schwartzberg, L., Piccart, M., Rugo, H. S., Yardley, D. A., Cortes, J., Untch, M., Harbeck, N., Wright, G. S., Bondarenko, I., Glaspy, J., Nowecki, Z., Kayali, et al
2021; 19 (2): 12–13
- **Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2-locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection**
Aftimos, P., Neven, P., Pegram, M., van Oord, C., Dees, E., Schroder, C., Jager, A., Bulat, I., Chap, L., Maglakelidze, M., Hamilton, E., Cristofanilli, M., Ulahannan, et al
AMER ASSOC CANCER RESEARCH.2021
- **Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC)**
Im, S., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., Rugo, H. S., Brown-Glaberman, U., Yardley, D. A., Kim, S., de Boer, M., Nowecki, Z., Glavicic, V., Wolf, et al
AMER ASSOC CANCER RESEARCH.2021
- **cGAS-STING pathway protein expression in human primary breast cancer**
Zong, Y., Liu, X., Barber, G. N., Pegram, M. D.
AMER ASSOC CANCER RESEARCH.2021
- **Infusion related reactions in the phase 3 SOPHIA trial of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with pretreated HER2+metastatic breast cancer**
Cortes, J., Cardoso, F., Curigliano, G., Gradishar, W. J., Im, S., Rugo, H. S., Bahadur, S. W., Falcone, A., Murillo, S., Riseberg, D. A., Musolino, A., Feinstein, T. M., Abreu, et al
AMER ASSOC CANCER RESEARCH.2021
- **Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2-locally advanced or metastatic breast cancer**
Aftimos, P., Maglakelidze, M., Glaudemans, A. M., Hamilton, E., Chap, L., de Vries, E., van Oordt, C., Jager, A., Dees, E., Cristofanilli, M., Pegram, M., Ulahannan, S., Neven, et al
AMER ASSOC CANCER RESEARCH.2021
- **Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors**
Dumbrava, E., Sharma, M. R., Carvajal, R. D., Catenacci, D., Emens, L. A., Gadgeel, S. M., Hanna, G. J., Juric, D., Kang, Y., Lee, J., Lee, K., Li, B. T., Moore, et al
AMER ASSOC CANCER RESEARCH.2021
- **Results from CONTESSA: A phase 3 study of tesseTaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus) metastatic breast cancer (MBC) who have previously received a taxane**
O'Shaughnessy, J., Schwartzberg, L., Piccart, M., Rugo, H. S., Yardley, D. A., Cortes, J., Untch, M., Harbeck, N., Wright, G. S., Bondarenko, I., Glaspy, J., Nowecki, Z., Kayali, et al
AMER ASSOC CANCER RESEARCH.2021

- **Health-related quality of life for margetuximab plus chemotherapy vs. trastuzumab plus chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+metastatic breast cancer**
Cardoso, F., Cortes, J., Gradishar, W., Im, S., Pegram, M. D., Rugo, H. S., Wright, G. S., De laurentiis, M., Levy, C., Ferrero, J., Mansi, J., Oyola, R., Ricci, et al
AMER ASSOC CANCER RESEARCH.2021
- **Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.** *JAMA oncology*
Rugo, H. S., Im, S. A., Cardoso, F. n., Cortés, J. n., Curigliano, G. n., Musolino, A. n., Pegram, M. D., Wright, G. S., Saura, C. n., Escrivá-de-Romaní, S. n., De Laurentiis, M. n., Levy, C. n., Brown-Glaberman, et al
2021
- **Single-cell immunoblotting resolves estrogen receptor-alpha isoforms in breast cancer.** *PLoS one*
Kim, J. J., Liang, W., Kang, C., Pegram, M. D., Herr, A. E.
2021; 16 (7): e0254783
- **Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.** *Clinical breast cancer*
Mahtani, R., Kittaneh, M., Kalinsky, K., Mamounas, E., Badve, S., Vogel, C., Lower, E., Schwartzberg, L., Pegram, M., Breast Cancer Therapy Expert Group (BCTEG)
2020
- **PATIENT-REPORTED OUTCOMES FOLLOWING PERTUZUMAB PLUS HIGH-DOSE TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) AND CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION POST-RADIOTHERAPY**
Kumthekar, P., Sahebjam, S., Pegram, M., Ibrahim, N., Sussell, J., Nicholas, A., Fung, A., Cheng, A., Lin, N. U.
OXFORD UNIV PRESS INC.2020: 174–75
- **PHASE 1/2 STUDY OF NOVEL HER2-TARGETING, TLR7/8 IMMUNE-STIMULATING ANTIBODY CONJUGATE (ISAC) BDC-1001 WITH OR WITHOUT IMMUNE CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED HER2-EXPRESSING SOLID TUMORS**
Sharma, M., Dumbrava, E., Carvajal, R., Catenacci, D., Emens, L., Hanna, G., Juric, D., Kang, Y., Lee, J., Lee, K., Li, B., Moore, K., Pegram, et al
BMJ PUBLISHING GROUP.2020: A244
- **Mitochondrial copper depletion suppresses triple-negative breast cancer in mice.** *Nature biotechnology*
Cui, L., Gouw, A. M., LaGory, E. L., Guo, S., Attarwala, N., Tang, Y., Qi, J., Chen, Y., Gao, Z., Casey, K. M., Bazhin, A. A., Chen, M., Hu, et al
2020
- **Intratumoral HER2 Heterogeneity in Breast Cancer** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
Pegram, M.
2020; 18 (9): 535–37
- **SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) plus Ctx versus trastuzumab (T) plus Ctx in patients (pts) with pretreated HER2+metastatic (met) breast cancer (MBC).**
Escriva, S., Im, S., Cardoso, F., Cortes, J., Curigliano, G., Gradishar, W., Pegram, M. D., Wright, G., Levy, C., De laurentiis, M., Ferrero, J., Bahadur, S., Kim, et al
AMER SOC CLINICAL ONCOLOGY.2020
- **Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.**
Pivot, X., Pegram, M. D., Cortes, J., Luftner, D., Rugo, H. S., Lyman, G. H., Curigliano, G., Bondarenko, I., Dvorkin, M., Yoon, Y., Kim, Y., Kim, C.
AMER SOC CLINICAL ONCOLOGY.2020
- **Immune cell repertoires in breast cancer patients after adjuvant chemotherapy.** *JCI insight*
Gustafson, C. E., Jadhav, R., Cao, W., Qi, Q., Pegram, M., Tian, L., Weyand, C. M., Goronzy, J. J.
2020; 5 (4)
- **Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis**
Rugo, H. S., Im, S., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., Musolino, A., Bachelot, T., Wright, G. S., De laurentiis, M., Kaufman, P. A., Pluard, T., Ricci, et al
AMER ASSOC CANCER RESEARCH.2020
- **CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor plus (HR plus) metastatic breast cancer (MBC) who have previously received a taxane**

O'Shaughnessy, J., Piccart, M., Schwartzberg, L., Cortes, J., Harbeck, N., Im, S., Rugo, H., Untch, M., Yardley, D., Bondarenko, I., Dieras, V., Pegram, M., Kroll, et al

AMER ASSOC CANCER RESEARCH.2020

- **Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results**
Gradishar, W. J., Im, S., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., Musolino, A., Berardi, R., De laurentiis, M., Bahadur, S. W., Im, Y., Lynch, C., Novik, et al
AMER ASSOC CANCER RESEARCH.2020
- **Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study**
Lin, N. U., Kumthekar, P., Sahebjam, S., Ibrahim, N., Fung, A., Cheng, A., Nicholas, A., Wang, B., Pegram, M.
AMER ASSOC CANCER RESEARCH.2020
- **Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)**
Murthy, R., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S., Lin, N., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, et al
AMER ASSOC CANCER RESEARCH.2020
- **Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).** *Clinical breast cancer*
Kittaneh, M. n., Badve, S. n., Caldera, H. n., Coleman, R. n., Goetz, M. P., Mahtani, R. n., Mamounas, E. n., Kalinsky, K. n., Lower, E. n., Pegram, M. n., Press, M. F., Rugo, H. S., Schwartzberg, et al
2020
- **Extracellular vesicle-mediated in vitro transcribed mRNA delivery for treatment of HER2+ breast cancer xenografts in mice by prodrug CB1954 without general toxicity.** *Molecular cancer therapeutics*
Forterre, A. V., Wang, J. H., Delcayre, A. n., Kim, K. n., Green, C. n., Pegram, M. D., Jeffrey, S. S., Matin, A. C.
2020
- **RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies.** *Frontiers in genetics*
van de Stolpe, A., Verhaegh, W., Blay, J., Ma, C. X., Pauwels, P., Pegram, M., Prenen, H., De Ruyscher, D., Saba, N. F., Slovin, S. F., Willard-Gallo, K., Husain, H.
2020; 11: 598118
- **Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Stebbing, J. n., Mainwaring, P. N., Curigliano, G. n., Pegram, M. n., Latymer, M. n., Bair, A. H., Rugo, H. S.
2020: JCO1902953
- **A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels.** *Molecular cancer therapeutics*
Barfield, R. M., Kim, Y. C., Chuprakov, S. n., Zhang, F. n., Bauzon, M. n., Ogunkoya, A. O., Yeo, D. n., Hickie, C. n., Pegram, M. D., Rabuka, D. n., Drake, P. M.
2020
- **Intratumoral HER2 heterogeneity in breast cancer.** *Clinical advances in hematology & oncology : H&O*
Pegram, M. n.
2020; 18 (9): 535–37
- **Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data.** *Clinical breast cancer*
Fernandes, L. E., Epstein, C. G., Bobe, A. M., Bell, J. S., Stumpe, M. C., Salazar, M. E., Salahudeen, A. A., Pe Benito, R. A., McCarter, C. n., Leibowitz, B. D., Kase, M. n., Igartua, C. n., Huether, et al
2020
- **Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.** *The New England journal of medicine*
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, et al

2019

- **SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) plus chemotherapy (C) versus trastuzumab (T) plus C in patients (pts) with HER2+metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).**
Rugo, H. S., Im, S., Wright, G., Escriva-de-Romani, S., DeLaurentiis, M., Cortes, J., Bahadur, S., Haley, B. B., Oyola, R. H., Riseberg, D. A., Musolino, A., Cardoso, F., Curigliano, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor plus (HR plus) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.**
O'Shaughnessy, J., Piccart, M., Schwartzberg, L. S., Cortes, J., Harbeck, N., Im, S., Rugo, H. S., Untch, M., Yardley, D. A., Bondarenko, I., Chan, S., Dieras, V., Pegram, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.**
Pivot, X., Pegram, M. D., Cortes, J., Luftner, D., Lyman, G. H., Curigliano, G., Bondarenko, I., Yoon, Y., Kim, Y., Lim, J.
AMER SOC CLINICAL ONCOLOGY.2019
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019; 37 (12): 946+
- **Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients** *CANCER MEDICINE*
Bakre, M. M., Ramkumar, C., Attuluri, A., Basavaraj, C., Prakash, C., Buturovic, L., Madhav, L., Naidu, N., Prathima, R., Somashekhar, S. P., Gupta, S., Doval, D., Pegram, et al
2019; 8 (4): 1755–64
- **Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.** *Cancer medicine*
Bakre, M. M., Ramkumar, C., Attuluri, A. K., Basavaraj, C., Prakash, C., Buturovic, L., Madhav, L., Naidu, N., R, P., Somashekhar, S. P., Gupta, S., Doval, D. C., Pegram, et al
2019
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019: JCO1802018
- **Induced Pluripotent Stem Cells as a Novel Cancer Vaccine.** *Expert opinion on biological therapy*
Wang, L. n., Pegram, M. D., Wu, J. C.
2019
- **A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.** *Clinical breast cancer*
Mahtani, R. n., Holmes, F. A., Badve, S. n., Caldera, H. n., Coleman, R. n., Mamounas, E. n., Kalinsky, K. n., Kittaneh, M. n., Lower, E. n., Pegram, M. n., Press, M. F., Rugo, H. S., Schwartzberg, et al
2019
- **Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.** *European journal of cancer (Oxford, England : 1990)*
Pivot, X. n., Pegram, M. n., Cortes, J. n., Lüftner, D. n., Lyman, G. H., Curigliano, G. n., Bondarenko, I. n., Yoon, Y. C., Kim, Y. n., Kim, C. n.
2019; 120: 1–9
- **HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Pegram, M. D., Miles, D. n., Tsui, C. K., Zong, Y. n.

2019

- **PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.** *British journal of cancer*
Pegram, M. D., Bondarenko, I., Zorretto, M. M., Hingmire, S., Iwase, H., Krivorotko, P. V., Lee, K. S., Li, R. K., Pikiel, J., Aggarwal, R., Ewesuedo, R., Freyman, A., Li, et al
2018
- **Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)** *BREAST CANCER RESEARCH AND TREATMENT*
Abraham, J., Coleman, R., Elias, A., Holmes, F., Kalinsky, K., Kittaneh, M., Lower, E., Mahtani, R., Mamounas, E., Pegram, M., Vogel, C., Breast Canc Therapy Expert Grp B
2018; 171 (1): 11–20
- **High caveolin-1 expression in African American women with early-stage triple-negative breast cancer**
Baumbach-Reardon, L. L., Getz, J., Ahearn, M. E., Carpten, J., Pegram, M.
AMER ASSOC CANCER RESEARCH.2018
- **Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer** *BREAST CANCER RESEARCH*
Norton, N., Fox, N., McCarl, C., Tenner, K. S., Ballman, K., Erskine, C. L., Necela, B. M., Northfelt, D., Tan, W. W., Calfa, C., Pegram, M., Colon-Otero, G., Perez, et al
2018; 20: 52
- **Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
Pegram, M. D., Zong, Y., Yam, C., Goetz, M. P., Moulder, S. L.
2018: 65–77
- **Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)** *BREAST CANCER RESEARCH AND TREATMENT*
Abraham, J., Caldera, H., Coleman, R., Elias, A., Goetz, M. P., Kittaneh, M., Lower, E., Mahtani, R., Mamounas, E., Pegram, M., Rugo, H., Schwartzberg, L., Traina, et al
2018; 169 (1): 1–7
- **Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution** *NPJ PRECISION ONCOLOGY*
Kang, C., Ward, T. M., Bockhorn, J., Schiffman, C., Huang, H., Pegram, M. D., Herr, A. E.
2018; 2: 10
- **Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation.** *Molecular cancer therapeutics*
Wang, J., Forterre, A. V., Zhao, J., Frimannsson, D. O., Delcayre, A., Antes, T. J., Efron, B., Jeffrey, S. S., Pegram, M. D., Matin, A. C.
2018
- **Targeted disruption of transcriptional effector GLI2 attenuates breast tumor growth and metastasis**
Beachy, P., Cai, S., Ma, Y., Hatakeyama, J., Zhao, C., Stoffels, M., Verhaegh, W., van de Stolpe, A., Pegram, M.
AMER ASSOC CANCER RESEARCH.2018
- **Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E. P., Naughton, M. J., Goetz, M. P., Russell, C., Tripathy, D., Cobleigh, M., Forero, et al
2017
- **Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.** *Clinical cancer research*
Baselga, J., Lewis Phillips, G. D., Verma, S., Ro, J., Huober, J., Guardino, A. E., Samant, M. K., Olsen, S., de Haas, S. L., Pegram, M. D.
2016; 22 (15): 3755-3763
- **Improved Survival of HER2(+) Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain** *CANCER RESEARCH*

- Knutson, K. L., Clynes, R., Shreeder, B., Yeramian, P., Kemp, K. P., Ballman, K., Tenner, K. S., Erskine, C. L., Norton, N., Northfelt, D., Tan, W., Calfa, C., Pegram, et al
2016; 76 (13): 3702-3710
- **Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer** *TUMOR BIOLOGY*
Liu, J., Chen, X., Ward, T., Pegram, M., Shen, K.
2016; 37 (7): 9825-9835
 - **Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer** *BREAST CANCER RESEARCH*
Krop, I. E., Modi, S., LoRusso, P. M., Pegram, M., Guardino, E., Althaus, B., Lu, D., Strasak, A., Elias, A.
2016; 18
 - **Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology** *ONCOTARGET*
Che, J., Yu, V., Dhar, M., Renier, C., Matsumoto, M., Heirich, K., Garon, E. B., Goldman, J., Rao, J., Sledge, G. W., Pegram, M. D., Sheth, S., Jeffrey, et al
2016; 7 (11): 12748-12760
 - **Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.** *international journal of biochemistry & cell biology*
Liu, J., Chen, X., Ward, T., Mao, Y., Bockhorn, J., Liu, X., Wang, G., Pegram, M., Shen, K.
2016; 71: 12-23
 - **Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting** *ADVANCED MATERIALS*
Duncombe, T. A., Kang, C., Maity, S., Ward, T. M., Pegram, M. D., Murthy, N., Herr, A. E.
2016; 28 (2): 327-334
 - **Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting.** *Advanced materials (Deerfield Beach, Fla.)*
Duncombe, T. A., Kang, C. C., Maity, S., Ward, T. M., Pegram, M. D., Murthy, N., Herr, A. E.
2016; 28 (2): 327-334
 - **Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.** *Breast cancer research*
Krop, I. E., Modi, S., LoRusso, P. M., Pegram, M., Guardino, E., Althaus, B., Lu, D., Strasak, A., Elias, A.
2016; 18 (1): 34-?
 - **"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.** *Clinical cancer research*
Sledge, G. W., Pegram, M. D.
2015; 21 (12): 2663-2665
 - **Everything old is neu again: cellular senescence in HER2-positive breast cancer.** *Journal of the National Cancer Institute*
Sledge, G. W., Pegram, M. D.
2015; 107 (5)
 - **Personalization of loco-regional care for primary breast cancer patients (part 1)** *FUTURE ONCOLOGY*
Toi, M., Winer, E. P., Benson, J. R., Inamoto, T., Forbes, J. F., von Minckwitz, G., Robertson, J. F., Grobmyer, S. R., Jatoi, I., Sasano, H., Kunkler, I., Ho, A. Y., Yamauchi, et al
2015; 11 (9): 1297-1300
 - **Personalization of loco-regional care for primary breast cancer patients (part 2)** *FUTURE ONCOLOGY*
Toi, M., Winer, E. P., Benson, J. R., Inamoto, T., Forbes, J. F., von Minckwitz, G., Robertson, J. F., Grobmyer, S. R., Jatoi, I., Sasano, H., Kunkler, I., Ho, A. Y., Yamauchi, et al
2015; 11 (9): 1301-1305
 - **Association Studies of Fc gamma Receptor Polymorphisms with Outcome in HER2(+) Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831** *CANCER IMMUNOLOGY RESEARCH*
Norton, N., Olson, R. M., Pegram, M., Tenner, K., Ballman, K. V., Clynes, R., Knutson, K. L., Perez, E. A.
2014; 2 (10): 962-969
 - **Assessing the Discordance Rate Between Local and Central HER2 Testing in Women With Locally Determined HER2-Negative Breast Cancer** *CANCER*

- Kaufman, P. A., Bloom, K. J., Burris, H., Gralow, J. R., Mayer, M., Pegram, M., Rugo, H. S., Swain, S. M., Yardley, D. A., Chau, M., Lalla, D., Yoo, B., Brammer, et al
2014; 120 (17): 2657-2664
- **Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Gradishar, W. J., Anderson, B. O., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., Goldstein, L. J., Hayes, D. F., Hudis, C. A., Isakoff, et al
2014; 12 (4): 542-590
 - **Breast cancer version 3.2014.** *Journal of the National Comprehensive Cancer Network*
Gradishar, W. J., Anderson, B. O., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., Goldstein, L. J., Hayes, D. F., Hudis, C. A., Isakoff, et al
2014; 12 (4): 542-590
 - **Treating the HER2 Pathway in Early and Advanced Breast Cancer** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Pegram, M. D.
2013; 27 (4): 751-?
 - **Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.** *Oncogene*
Ward, T. M., IORNS, E., Liu, X., Hoe, N., Kim, P., Singh, S., Dean, S., Jegg, A., Gallas, M., Rodriguez, C., Lippman, M., Landgraf, R., Pegram, et al
2013; 32 (19): 2463-2474
 - **The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.** *Breast cancer research and treatment*
Hurley, J., Reis, I. M., Rodgers, S. E., Gomez-Fernandez, C., Wright, J., Leone, J. P., Larrieu, R., Pegram, M. D.
2013; 138 (3): 783-794
 - **PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+breast cancer cells** *BREAST CANCER RESEARCH AND TREATMENT*
Jegg, A., Ward, T. M., Iorns, E., Hoe, N., Zhou, J., Liu, X., Singh, S., Landgraf, R., Pegram, M. D.
2012; 136 (3): 683-692
 - **Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference** *BREAST CANCER RESEARCH AND TREATMENT*
Toi, M., Benson, J. R., Winer, E. P., Forbes, J. F., von Minckwitz, G., Golshan, M., Robertson, J. F., Sasano, H., Cole, B. F., Chow, L. W., Pegram, M. D., Han, W., Huang, et al
2012; 136 (3): 919-926
 - **Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer** *NEW ENGLAND JOURNAL OF MEDICINE*
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D., Dieras, V., Guardino, E., Fang, L., Lu, M. W., Olsen, et al
2012; 367 (19): 1783-1791
 - **Comprehensive molecular portraits of human breast tumours** *NATURE*
Koboldt, D. C., Fulton, R. S., McLellan, M. D., Schmidt, H., Kalicki-Veizer, J., McMichael, J. F., Fulton, L. L., Dooling, D. J., Ding, L., Mardis, E. R., Wilson, R. K., Ally, A., Balasundaram, et al
2012; 490 (7418): 61-70
 - **Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor** *BREAST CANCER RESEARCH AND TREATMENT*
Iorns, E., Ward, T. M., Dean, S., Jegg, A., Thomas, D., Murugaesu, N., Sims, D., Mitsopoulos, C., Fenwick, K., Kozarewa, I., Naceur-Lombarelli, C., Zvelebil, M., Isacke, et al
2012; 135 (1): 79-91
 - **Tumor Biology Trumps Anatomy in Breast Cancer Brain Metastases** *ONCOLOGY-NEW YORK*
Pegram, M. D.
2012; 26 (7): 666-?
 - **Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer** *BREAST CANCER*
Araki, K., Saji, S., Gallas, M., Pegram, M., Sasaki, Y.

2012; 19 (2): 95-103

- **Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer** *BREAST CANCER RESEARCH AND TREATMENT*
Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J., Koniaris, L. G., Rumboldt, T., Yasir, S., Jorda, M., Garret-Mayer, E., Avisar, E., Slingerland, J., Silva, O., Welsh, et al
2012; 132 (1): 215-223
- **Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions** *CLINICAL BREAST CANCER*
Pegram, M., Liao, J.
2012; 12 (1): 10-18
- **Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer** *CLINICAL CANCER RESEARCH*
Ibrahim, N. K., Yariz, K. O., Bondarenko, I., Manikhas, A., Semiglazov, V., Alyasova, A., Komisarenko, V., Shparyk, Y., Murray, J. L., Jones, D., Senderovich, S., Chau, A., Erlandsson, et al
2011; 17 (21): 6822-6830
- **HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis** *BREAST CANCER RESEARCH AND TREATMENT*
Houssami, N., Macaskill, P., Balleine, R. L., Bilous, M., Pegram, M. D.
2011; 129 (3): 659-674
- **Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer** *CARCINOGENESIS*
Smith, T. R., Liu-Mares, W., Van Emburgh, B. O., Levine, E. A., Allen, G. O., Hill, J. W., Reis, I. M., Kresty, L. A., Pegram, M. D., Miller, M. S., Hu, J. J.
2011; 32 (9): 1354-1360
- **Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens** *JOURNAL OF CLINICAL ONCOLOGY*
Valero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J. R., Fumoleau, P., Rolski, J., Mrcic-Krmpotic, et al
2011; 29 (2): 149-156
- **Proceedings of the First Global Workshop on Breast Cancer: Pathways to the Evaluation and Clinical Development of Novel Agents for Breast Cancer** *CLINICAL BREAST CANCER*
Albain, K. S., Carey, L., Gradishar, W. J., Gralow, J. R., Lipton, A., Rugo, H., Tripathy, D., Peck, S., Abair, T., Pegram, M.
2010; 10 (6): 421-439
- **Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene.** *Breast care (Basel, Switzerland)*
Harbeck, N., Pegram, M. D., Rüschoff, J., Möbus, V.
2010; 5 (s1): 3-7
- **Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer** *BRITISH JOURNAL OF CANCER*
Royer, B., Yin, W., Pegram, M., Ibrahim, N., Villanueva, C., Mir, D., Erlandsson, F., Pivot, X.
2010; 102 (5): 827-832
- **Lapatinib: new opportunities for management of breast cancer.** *Breast cancer (Dove Medical Press)*
Liao, J., Gallas, M., Pegram, M., Slingerland, J.
2010; 2: 79-91
- **Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., Press, M. F., Maltzman, J., Florance, et al
2009; 27 (33): 5538-5546
- **Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens** *ANNALS OF ONCOLOGY*
Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., Maltzman, J. D., Forster, J. K., Rubin, S. D., Stein, S. H., Burstein, H. J.

2009; 20 (6): 1026-1031

- **Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer** *BREAST CANCER RESEARCH*
Pegram, M. D., Borges, V. F., Ibrahim, N., Fuloria, J., Shapiro, C., Perez, S., Wang, K., Stark, F. S., Luck, N. C.
2009; 11 (5)
- **Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer** *28th Annual San Antonio Breast Cancer Symposium*
Storniolo, A. M., Pegram, M. D., Overmoyer, B., Silverman, P., Peacock, N. W., Jones, S. F., Loftiss, J., Arya, N., Koch, K. M., Paul, E., Pandite, L., Fleming, R. A., Lebowitz, et al
AMER SOC CLINICAL ONCOLOGY.2008: 3317-23
- **Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?** *CLINICAL BREAST CANCER*
Pegram, M.
2008; 8: S121-S130
- **Biodistribution and predictive value of (IF)-I-18-fluorocyclophosphamide in mice bearing human breast cancer xenografts** *JOURNAL OF NUCLEAR MEDICINE*
Kesner, A. L., Hsueh, W., Htet, N. L., Pio, B. S., Czernin, J., Pegram, M. D., Phelps, M. E., Silverman, D. H.
2007; 48 (12): 2021-2027
- **American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, et al
2007; 25 (1): 118-145
- **American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer** *ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE*
Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, et al
2007; 131 (1): 18-43
- **Predicting chemotherapy response to paclitaxel with F-18-fluoropaclitaxel and PET** *JOURNAL OF NUCLEAR MEDICINE*
Hsueh, W., Kesner, A. L., Gangloff, A., Pegram, M. D., Beryt, M., Czernin, J., Phelps, M. E., Silverman, D. H.
2006; 47 (12): 1995-1999
- **Clinical activity of Pertuzumab (rhuMab 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status** *41st Annual Meeting of the American-Society-of-Clinical-Oncology*
Gordon, M. S., Matei, D., Aghajanian, C., Matulonis, U. A., Brewer, M., Fleming, G. F., Hainsworth, J. D., Garcia, A. A., Pegram, M. D., Schilder, R. J., Cohn, D. E., Roman, L., Derynck, et al
AMER SOC CLINICAL ONCOLOGY.2006: 4324-32
- **Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin((R))): A case study** *ADVANCED DRUG DELIVERY REVIEWS*
Pegram, M., Ngo, D.
2006; 58 (5-6): 723-734
- **Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents** *1st International Symposium on Cancer Metastasis and the Lymphovascular System*
Holash, J., Thurston, G., Rudge, J. S., Yancopoulos, G. D., Adjei, A. A., Bergers, G., Pytowski, B., Pegram, M., Gordon, M. S.
SPRINGER.2006: 243-52
- **Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer** *26th Annual San Antonio Breast Cancer Symposium*
Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Pegram, M. D., Slamon, D. J.
AMER SOC CLINICAL ONCOLOGY.2006: 1831-38
- **Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1** *41st Annual Meeting of the American-Society-of-Clinical-Oncology*
Ryan, B. M., Konecny, G. E., Kahlert, S., Wang, H. J., Untch, M., Meng, G., Pegram, M. D., Podratz, K. C., Crown, J., Slamon, D. J., Duffy, M. J.

OXFORD UNIV PRESS.2006: 597-604

- **Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells** *CANCER RESEARCH*
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G. R., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., Keith, B. R., Gilmer, T. M., Berger, et al
2006; 66 (3): 1630-1639
- **Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy** *MOLECULAR IMAGING AND BIOLOGY*
Pio, B. S., Park, C. K., Pietras, R., Hsueh, W. A., Satyamurthy, N., Pegram, M. D., Czernin, J., Phelps, M. E., Silverman, D. H.
2006; 8 (1): 36-42
- **Reducing the global breast cancer burden: the importance of patterns of care research.** *Clinical breast cancer*
Albain, K. S., De la Garza Salazar, J., Pienkowski, T., Aapro, M., Bergh, J., Caleffi, M., Coleman, R., Eiermann, W., Icli, F., Pegram, M., Piccart, M., Snyder, R., Toi, et al
2005; 6 (5): 412-420
- **Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with F-18-fluoropaclitaxel** *JOURNAL OF NUCLEAR MEDICINE*
Gangloff, A., Hsueh, W. A., Kesner, A. L., Kiesewetter, D. O., Pio, B. S., Pegram, M. D., Beryt, M., Townsend, A., Czernin, J., Phelps, M. E., Silverman, D. H.
2005; 46 (11): 1866-1871
- **Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer** *INVESTIGATIONAL NEW DRUGS*
Yeon, C. H., Pegram, M. D.
2005; 23 (5): 391-409
- **Image-detected breast cancer: State of the art diagnosis and treatment** *JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS*
Silverstein, M. J., Lagios, M. D., Recht, A., Allred, D. C., Harms, S. E., Holland, R., Holmes, D. R., Hughes, L. L., Jackman, R. J., Julian, T. B., Kuerer, H. M., Mabry, H. C., McCready, et al
2005; 201 (4): 586-597
- **Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy** *ANTI-CANCER DRUGS*
Pal, S. K., Pegram, M.
2005; 16 (5): 483-494
- **Targeted therapy: Wave of the future** *JOURNAL OF CLINICAL ONCOLOGY*
Pegram, M. D., Pietras, R., Bajamonde, A., Klein, P., Fyfe, G.
2005; 23 (8): 1776-1781
- **Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.** *Oncology (Williston Park, N.Y.)*
Konecny, G. E., Pegram, M. D.
2004; 18 (14): 32-36
- **Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer.** *Techniques in coloproctology*
Emmanouilides, C., Pegram, M., Robinson, R., Hecht, R., Kabbinar, F., Isacoff, W.
2004; 8: s50-2
- **HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer** *37th Annual Meeting of the American-Society-of-Clinical-Oncology*
Konecny, G. E., Thomssen, C., Luck, H. J., Untch, M., Wang, H. J., Kuhn, W., Eidtmann, H., du Bois, A., Olbricht, S., Steinfeld, D., MOBUS, V., von Minckwitz, G., Dandekar, et al
OXFORD UNIV PRESS INC.2004: 1141-51
- **Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., Fumoleau, P., Quan, E., Crown, J., Toppmeyer, D., Smylie, M., Riva, A., Blitz, S., Press, et al
2004; 96 (10): 759-769

- **Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., Slamon, D. J.
2004; 96 (10): 739-749
- **Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients** *CLINICAL CANCER RESEARCH*
Konecny, G. E., Meng, Y. G., Untch, M., Wang, H. J., Bauerfeind, I., Epstein, M., Stieber, P., Vernes, J. M., Gutierrez, J., Hong, K., Beryt, M., Hepp, H., Slamon, et al
2004; 10 (5): 1706-1716
- **Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H. M., Bauerfeind, I., Felber, M., Wang, H. J., Beryt, M., Seshadri, et al
2003; 95 (2): 142-153
- **Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.** *Journal of experimental therapeutics & oncology*
Gilbert, C. W., McGowan, E. B., Seery, G. B., Black, K. S., Pegram, M. D.
2003; 3 (1): 27-35
- **Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy** *BREAST CANCER RESEARCH AND TREATMENT*
Crown, J., Pegram, M.
2003; 79: S11-S18
- **A human ovarian carcinoma murine xenograft model useful for preclinical trials** *GYNECOLOGIC ONCOLOGY*
Elkas, J. C., Baldwin, R. L., Pegram, M., Tseng, Y., Slamon, D., Karlan, B. Y.
2002; 87 (2): 200-206
- **Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500** *9th International Conference on Gene Therapy of Cancer*
Buller, R. E., Shahin, M. S., Horowitz, J. A., Runnebaum, I. B., Mahavni, V., Petrauskas, S., KREIENBERG, R., Karlan, B., Slamon, D., Pegram, M.
NATURE PUBLISHING GROUP.2002: 567-72
- **A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer** *30th Annual Meeting of the Society-of-Gynecologic-Oncologists*
Buller, R. E., Runnebaum, I. B., Karlan, B. Y., Horowitz, J. A., Shahin, M., Buekers, T., Petrauskas, S., KREIENBERG, R., Slamon, D., Pegram, M.
NATURE PUBLISHING GROUP.2002: 553-66
- **Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor** *SEMINARS IN ONCOLOGY*
Pegram, M. D., Reese, D. M.
2002; 29 (3): 29-37
- **Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction** *MOLECULAR CANCER THERAPEUTICS*
Neuteboom, S. T., Karjian, P. L., Boyer, C. R., Beryt, M., Pegram, M., Wahl, G. M., SHEPARD, H. M.
2002; 1 (6): 377-384
- **Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.** *Clinical breast cancer*
Pegram, M. D., O'Callaghan, C.
2001; 2: S15-9
- **HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer** *CLINICAL CANCER RESEARCH*
Konecny, G., Untch, M., Arboleda, J., Wilson, C., Kahlert, S., Boettcher, B., Felber, M., Beryt, M., Lude, S., Hepp, H., Slamon, D., Pegram, M.
2001; 7 (8): 2448-2457
- **Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer** *CLINICAL CANCER RESEARCH*

- Konecny, G., Untch, M., Pihan, A., Kimmig, R., Gropp, M., Stieber, P., Hepp, H., Slamon, D., Pegram, M.
2001; 7 (6): 1743-1749
- **Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples** *BREAST CANCER RESEARCH AND TREATMENT*
Konecny, G., Untch, M., Slamon, D., Beryt, M., Kahlert, S., Felber, M., LANGER, E., Lude, S., Hepp, H., Pegram, M.
2001; 67 (3): 223-233
 - **Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.** *NEW ENGLAND JOURNAL OF MEDICINE*
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, L.
2001; 344 (11): 783-792
 - **Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials** *SEMINARS IN ONCOLOGY*
Slamon, D., Pegram, M.
2001; 28 (1): 13-19
 - **Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase** *NCI-EORTC Symposium on Chemotherapeutic Strategies for Treatment of Colorectal Cancer: Present and Future Developments*
Lackey, D. B., Groziak, M. P., Sergeeva, M., Beryt, M., Boyer, C., Stroud, R. M., Sayre, P., Park, J. W., Johnston, P., Slamon, D., SHEPARD, H. M., Pegram, M.
PERGAMON-ELSEVIER SCIENCE LTD.2001: 179-89
 - **Docetaxel and Herceptin: Foundation for future strategies** *Symposium on Innovative Therapies in Breast Cancer*
Pegram, M. D.
ALPHAMED PRESS.2001: 22-25
 - **HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer** *BREAST CANCER RESEARCH AND TREATMENT*
Konecny, G., FRITZ, M., Untch, M., Lebeau, A., Felber, M., Lude, S., Beryt, M., Hepp, H., Slamon, D., Pegram, M.
2001; 69 (1): 53-63
 - **HER-2/neu as a predictive marker in breast cancer** *GEBURTSHILFE UND FRAUENHEILKUNDE*
Konecny, G., Pegram, M., Untch, M., Thomssen, C., JANICKE, F., Hepp, H., Slamon, D. J.
2000; 60 (12): 609-619
 - **Trastuzumab and chemotherapeutics: Drug interactions and synergies** *SEMINARS IN ONCOLOGY*
Pegram, M. D., Lopez, A., Konecny, G., Slamon, D. J.
2000; 27 (6): 21-25
 - **Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy** *SEMINARS IN ONCOLOGY*
Pegram, M., Slamon, D.
2000; 27 (5): 13-19
 - **Docetaxel and trastuzumab: A combination with clinical relevance** *Symposium on a New Era in Oncology*
Konecny, G., Pegram, M., Slamon, D.
KARGER.2000: 7-9
 - **Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer** *GYNECOLOGIC ONCOLOGY*
Konecny, G., Crohns, C., Pegram, M., Felber, M., Lude, S., Kurbacher, C., Cree, I. A., Hepp, H., Untch, M.
2000; 77 (2): 258-263
 - **The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.** *Cancer treatment and research*
Pegram, M. D., Konecny, G., Slamon, D. J.
2000; 103: 57-75
 - **A model-based approach for assessing in vivo combination therapy interactions** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*

- Lopez, A. M., Pegram, M. D., Slamon, D. J., Landaw, E. M.
1999; 96 (23): 13023-13028
- **Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells** *ONCOGENE*
Aguilar, Z., Akita, R. W., Finn, R. S., Ramos, B. L., Pegram, M. D., Kabbinavar, F. F., Pietras, R. J., Pisacane, P., Sliwkowski, M. X., Slamon, D. J.
1999; 18 (44): 6050-6062
 - **Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity** *Medical Oncologist Consensus Conference on the Future Directions with Herceptin (Trastuzumab) for Breast Cancer*
Pegram, M. D., Slamon, D. J.
W B SAUNDERS CO-ELSEVIER INC.1999: 89-95
 - **Herceptin in the treatment of metastatic breast cancer** *GYNKOLOGE*
Konecny, G., Untch, M., Pegram, M.
1999; 32 (8): 624-631
 - **Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers** *ONCOGENE*
Pegram, M., HSU, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., Slamon, D.
1999; 18 (13): 2241-2251
 - **Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs** *ONCOGENE*
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., Slamon, D. J.
1998; 17 (17): 2235-2249
 - **Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment** *JOURNAL OF CLINICAL ONCOLOGY*
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., Slamon, D. J.
1998; 16 (8): 2659-2671
 - **Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta 1** *BIOCHEMISTRY*
Landgraf, R., Pegram, M., Slamon, D. J., Eisenberg, D.
1998; 37 (9): 3220-3228
 - **HER-2/neu as a predictive marker of response to breast cancer therapy** *BREAST CANCER RESEARCH AND TREATMENT*
Pegram, M. D., Pauletti, G., Slamon, D. J.
1998; 52 (1-3): 65-77
 - **Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas** *ONCOGENE*
MacGrogan, D., Pegram, M., Slamon, D., Bookstein, R.
1997; 15 (9): 1111-1114
 - **The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells** *ONCOGENE*
Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., Slamon, D. J.
1997; 15 (5): 537-547
 - **Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies** *INTERNATIONAL JOURNAL OF ONCOLOGY*
Nguyen, M., Tran, C., Barsky, S., Sun, J. R., McBride, W., Pegram, M., Pietras, R., Love, S., Glaspy, J.
1997; 10 (5): 965-969
 - **HER-3 TYROSINE KINASE PATHWAY TARGETS ESTROGEN-RECEPTOR AND PROMOTES HORMONE-INDEPENDENT GROWTH IN HUMAN BREAST-CANCER CELLS** *ONCOGENE*
Pietras, R. J., Arboleda, J., Reese, D. M., WONGVIPAT, N., Pegram, M. D., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. X., Slamon, D. J.
1995; 10 (12): 2435-2446
 - **ANTIBODY TO HER-2/NEU RECEPTOR BLOCKS DNA-REPAIR AFTER CISPLATIN IN HUMAN BREAST AND OVARIAN-CANCER CELLS** *ONCOGENE*

Pietras, R. J., Fendly, B. M., CHAZIN, V. R., Pegram, M. D., Howell, S. B., Slamon, D. J.
1994; 9 (7): 1829-1838

● **DIAGNOSIS OF INFECTIVE AND INFLAMMATORY DISORDERS BY FLOW CYTOMETRIC ANALYSIS OF BLOOD NEUTROPHILS** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*

Bentley, S. A., Pegram, M. D., Ross, D. W.
1987; 88 (2): 177-181